Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer | Zendy

Yunpeng Yang | Zendy; Bin Wu | Zendy; Linian Huang | Zendy; Meiqi Shi | Zendy; Yunpeng Liu | Zendy; Yanqiu Zhao | Zendy; Lijun Wang | Zendy; Shun Lü | Zendy; Gongyan Chen | Zendy; Baolan Li | Zendy; Conghua Xie | Zendy; Jian Fang | Zendy; g Yang | Zendy; Yiping Zhang | Zendy; Jiuwei Cui | Zendy; Yong Song | Zendy; Cuiying Zhang | Zendy; Xiaodong Mei | Zendy; Bangwei Cao | Zendy; Lan Yang | Zendy; Ying Cheng | Zendy; Kejing Ying | Zendy; Tao Sun | Zendy; Biyong Ren | Zendy; Qitao Yu | Zendy; Zijun Liao | Zendy; Zhidong Pei | Zendy; Mengzhao Wang | Zendy; Jianying Zhou | Zendy; Shiying Yu | Zendy; Guosheng Feng | Zendy; Huiping Wan | Zendy; Huaqing Wang | Zendy; Shegan Gao | Zendy; Jinliang Wang | Zendy; Guangyu An | Zendy; Yi Geng | Zendy; Yanxia Ji | Zendy; Ying Yuan | Zendy; Shenglin Ma | Zendy; Zhongyao Jia | Zendy; Mu Hu | Zendy; Hui Zhou | Zendy; Jie Yu | Zendy; Xing Sun | Zendy; Li Zhang | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Biosimilar candidate IBI305 plus paclitaxel/carboplatin for the treatment of non-squamous non-small cell lung cancer

Author(s) -

Yunpeng Yang,

Bin Wu,

Linian Huang,

Meiqi Shi,

Yunpeng Liu,

Yanqiu Zhao,

Lijun Wang,

Shun Lü,

Gongyan Chen,

Baolan Li,

Conghua Xie,

Jian Fang,

g Yang,

Yiping Zhang,

Jiuwei Cui,

Yong Song,

Cuiying Zhang,

Xiaodong Mei,

Bangwei Cao,

Lan Yang,

Ying Cheng,

Kejing Ying,

Tao Sun,

Biyong Ren,

Qitao Yu,

Zijun Liao,

Zhidong Pei,

Mengzhao Wang,

Jianying Zhou,

Shiying Yu,

Guosheng Feng,

Huiping Wan,

Huaqing Wang,

Shegan Gao,

Jinliang Wang,

Guangyu An,

Yi Geng,

Yanxia Ji,

Ying Yuan,

Shenglin Ma,

Zhongyao Jia,

Mu Hu,

Hui Zhou,

Jie Yu,

Xing Sun,

Li Zhang

Publication year - 2019

Publication title -

translational lung cancer research

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.474

H-Index - 41

eISSN - 2226-4477

pISSN - 2218-6751

DOI - 10.21037/tlcr.2019.12.23

Subject(s) - bevacizumab , medicine , carboplatin , lung cancer , oncology , clinical endpoint , paclitaxel , adverse effect , vascular endothelial growth factor , chemotherapy , randomized controlled trial , cisplatin , vegf receptors

Bevacizumab is a monoclonal antibody (mAb) against vascular endothelial growth factor (VEGF) and used for treatments of various cancers. Due to the high costs of bevacizumab treatments, a biosimilar provides an affordable alternative therapy for cancer patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research